KMYY(SH:600518) 智通财经网·2025-08-29 09:59Core Viewpoint - Kangmei Pharmaceutical (600518.SH) reported a revenue of 2.577 billion yuan for the first half of 2025, reflecting a year-on-year growth of 4.17% [1] - The company's net profit attributable to shareholders reached 16.9 million yuan, marking a year-on-year increase of 7.24% [1] - The company reported a non-recurring net profit loss of 3.62 million yuan, with basic earnings per share at 0.001 yuan [1] Financial Performance - Revenue for the reporting period was 2.577 billion yuan, up 4.17% compared to the previous year [1] - Net profit attributable to shareholders was 16.9 million yuan, an increase of 7.24% year-on-year [1] - Non-recurring net profit showed a loss of 362,000 yuan [1] - Basic earnings per share stood at 0.001 yuan [1]